Aura Biosciences (AURA) investor relations material

Executive summary

• Natalie Holles appointed as Chief Executive Officer and President, effective April 30, 2026, succeeding founder Dr. Elisabet de los Pinos.

• Dr. de los Pinos will provide consulting services through October 30, 2026, with equity vesting and severance arrangements.

• Phase 3 Compass trial for belzupacap sarotalocan (bel-sar) in early choroidal melanoma is nearing enrollment completion, with 86 patients enrolled and over 25 more scheduled or identified for screening.

• Enrollment completion is expected by mid-2026, with topline data anticipated in the second half of 2027.

• The company terminated its ATM Prospectus, having raised $6.7 million through the sale of 1,055,362 shares.

Voting matters and shareholder proposals

• Board appointments include Natalie Holles as CEO, President, and Class I director with a term expiring at the 2028 annual meeting.

Board of directors and corporate governance

• Natalie Holles joins the board as a Class I director; no family relationships or arrangements with other directors or officers.

• Dr. de los Pinos departs from all executive and board roles, with a transition to a consulting position.